Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.
Daiichi Sankyo has submitted an application to Japanese regulatory authorities asking that its investigational therapy trastuzumab deruxtecan (DS-8201) be approved as a treatment for people with HER2-positive metastatic breast cancer. ... Read more
The first patients have been dosed in a Phase 1 trial evaluating Arvinas‘ experimental therapy ARV-471 for locally-advanced or metastatic ER-positive, HER2-negative breast cancer. Approximately 80% of newly-diagnosed breast cancers ... Read more
Trilaciclib, a treatment that protects the bone marrow from the damaging effects of chemotherapy, significantly extends the lives of women with metastatic triple-negative breast cancer receiving a chemotherapy regimen of ... Read more
Clofazimine, an antibiotic long used for treating leprosy and tuberculosis, may be repurposed as a promising potential treatment for triple-negative breast cancer, a study in mice suggests. The treatment targets the ... Read more
Specific changes in gene expression might help to predict the risk of relapse in estrogen receptor (ER)-positive breast cancer patients under hormone therapy, a study reports. The study, “Molecular changes ... Read more
The number of circulating tumor cells (CTCs) could help doctors choose between hormone therapy or chemotherapy for the first-line treatment of metastatic breast cancer patients whose tumors produce estrogen receptor ... Read more
Adding Pfizer’s Ibrance (palbociclib) to standard treatment Faslodex (fulvestrant) significantly extended the survival of advanced breast cancer patients in a Phase 3 clinical trial, researchers report. Called PALOMA-3, the trial (NCT01942135) specifically ... Read more